Insider transactions

EDGAR

Septerna, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-21.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
43 transactions, 1,923,134 shares
Sum of shares × price per share: 81,715,048.1073

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 104

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-11-16 Filed 2026-11-18Labrucherie Gil M Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)15,81541.4754
655,933.451

Derived: shares × price per share. Exact value 655933.4510.

24,185Indirect (I) By TrustYes
F1, F2, F3
  • F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on July 22, 2026.
  • F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.85 to $41.845. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  • F3 The shares are held directly by The Labrucherie Trust dated 9/1/2009, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
Open filing 0001193125-26-467395 Read from the filing’s XML Dispute this row
2026-11-16 Filed 2026-11-18Labrucherie Gil M Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)3,48541.9873
146,325.7405

Derived: shares × price per share. Exact value 146325.7405.

20,700Indirect (I) By TrustYes
F1, F4, F3
  • F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on July 22, 2026.
  • F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.85 to $42.14. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  • F3 The shares are held directly by The Labrucherie Trust dated 9/1/2009, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
Open filing 0001193125-26-467395 Read from the filing’s XML Dispute this row
2026-11-16 Filed 2026-11-18Labrucherie Gil M Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)70043
30,100

Derived: shares × price per share. Exact value 30100.

20,000Indirect (I) By TrustYes
F1, F3
  • F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on July 22, 2026.
  • F3 The shares are held directly by The Labrucherie Trust dated 9/1/2009, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
Open filing 0001193125-26-467395 Read from the filing’s XML Dispute this row
2026-11-12 Filed 2026-11-16Finer Jeffrey Director · Officer: Chief Executive Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)18,5002.76
51,060

Derived: shares × price per share. Exact value 51060.00.

852,409Direct (D) Yes
F1
  • F1 Includes 3,501 shares acquired under the Septerna, Inc. 2024 Employee Stock Purchase Plan (ESPP) on October 31, 2025 and 3,501 shares acquired under the ESPP on April 30, 2026 in transactions that were exempt under Rule 16b-3(c).
Open filing 0001193125-26-464072 Read from the filing’s XML Dispute this row
2026-11-12 Filed 2026-11-16Finer Jeffrey Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)5,60042.0888
235,697.28

Derived: shares × price per share. Exact value 235697.2800.

846,809Direct (D) Yes
F2, F3
  • F2 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 11, 2026.
  • F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.68 to $42.67. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Open filing 0001193125-26-464072 Read from the filing’s XML Dispute this row
2026-11-12 Filed 2026-11-16Finer Jeffrey Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)5,30043.0959
228,408.27

Derived: shares × price per share. Exact value 228408.2700.

841,509Direct (D) Yes
F2, F4
  • F2 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 11, 2026.
  • F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.68 to $43.48. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Open filing 0001193125-26-464072 Read from the filing’s XML Dispute this row
2026-11-12 Filed 2026-11-16Finer Jeffrey Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,80044.2261
123,833.08

Derived: shares × price per share. Exact value 123833.0800.

838,709Direct (D) Yes
F2, F5
  • F2 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 11, 2026.
  • F5 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.69 to $44.63. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Open filing 0001193125-26-464072 Read from the filing’s XML Dispute this row
2026-11-12 Filed 2026-11-16Finer Jeffrey Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,82345.2751
127,811.6073

Derived: shares × price per share. Exact value 127811.6073.

835,886Direct (D) Yes
F2, F6
  • F2 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 11, 2026.
  • F6 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $44.85 to $45.83. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Open filing 0001193125-26-464072 Read from the filing’s XML Dispute this row
2026-11-12 Filed 2026-11-16Finer Jeffrey Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,97746.1631
91,264.4487

Derived: shares × price per share. Exact value 91264.4487.

833,909Direct (D) Yes
F2, F7
  • F2 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 11, 2026.
  • F7 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.86 to $46.75. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Open filing 0001193125-26-464072 Read from the filing’s XML Dispute this row
2026-11-12 Filed 2026-11-16Finer Jeffrey Director · Officer: Chief Executive Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (18,500) — exercise price 2.76
Disposed (D)18,5000—378,712Direct (D) Yes
F8
  • F8 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of August 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date.
Open filing 0001193125-26-464072 Read from the filing’s XML Dispute this row
2026-11-11 Filed 2026-11-13Ezekowitz Alan Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)6,93946.005
319,228.695

Derived: shares × price per share. Exact value 319228.695.

110,481Direct (D) Yes
F1, F2
  • F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on July 13, 2026.
  • F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.36 to $46.35. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Open filing 0001193125-26-461248 Read from the filing’s XML Dispute this row
2026-11-11 Filed 2026-11-13Ezekowitz Alan Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)13,20147.0116
620,600.1316

Derived: shares × price per share. Exact value 620600.1316.

97,280Direct (D) Yes
F1, F3
  • F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on July 13, 2026.
  • F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.37 to $47.36. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Open filing 0001193125-26-461248 Read from the filing’s XML Dispute this row
2026-11-11 Filed 2026-11-13Ezekowitz Alan Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)22,86547.7799
1,092,487.4135

Derived: shares × price per share. Exact value 1092487.4135.

74,415Direct (D) Yes
F1, F4
  • F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on July 13, 2026.
  • F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $47.37 to $48.35. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Open filing 0001193125-26-461248 Read from the filing’s XML Dispute this row
2026-11-11 Filed 2026-11-13Ezekowitz Alan Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)31,57248.7002
1,537,562.7144

Derived: shares × price per share. Exact value 1537562.7144.

42,843Direct (D) Yes
F1, F5
  • F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on July 13, 2026.
  • F5 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.37 to $49.33. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Open filing 0001193125-26-461248 Read from the filing’s XML Dispute this row
2026-11-11 Filed 2026-11-13Ezekowitz Alan Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)4,17549.6465
207,274.1375

Derived: shares × price per share. Exact value 207274.1375.

38,668Direct (D) Yes
F1, F6
  • F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on July 13, 2026.
  • F6 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.38 to $50.31. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Open filing 0001193125-26-461248 Read from the filing’s XML Dispute this row
2026-11-11 Filed 2026-11-13Ezekowitz Alan Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,01350.897
102,455.661

Derived: shares × price per share. Exact value 102455.661.

36,655Direct (D) Yes
F1, F7
  • F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on July 13, 2026.
  • F7 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.47 to $51.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Open filing 0001193125-26-461248 Read from the filing’s XML Dispute this row
2026-11-11 Filed 2026-11-13Ezekowitz Alan Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,05551.9
54,754.5

Derived: shares × price per share. Exact value 54754.5.

35,600Direct (D) Yes
F1
  • F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on July 13, 2026.
Open filing 0001193125-26-461248 Read from the filing’s XML Dispute this row
2026-10-15 Filed 2026-10-19Bhatt Elizabeth Officer: President and COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)4,0006.81
27,240

Derived: shares × price per share. Exact value 27240.00.

178,209Direct (D) Yes— Open filing 0001193125-26-425485 Read from the filing’s XML Dispute this row
2026-10-15 Filed 2026-10-19Bhatt Elizabeth Officer: President and COO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,09436.8715
40,337.421

Derived: shares × price per share. Exact value 40337.4210.

177,115Direct (D) Yes
F1, F2
  • F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on October 20, 2025.
  • F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.24 to $37.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Open filing 0001193125-26-425485 Read from the filing’s XML Dispute this row
2026-10-15 Filed 2026-10-19Bhatt Elizabeth Officer: President and COO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,90637.6142
109,306.8652

Derived: shares × price per share. Exact value 109306.8652.

174,209Direct (D) Yes
F1, F3
  • F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on October 20, 2025.
  • F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.31 to $38.07. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Open filing 0001193125-26-425485 Read from the filing’s XML Dispute this row
2026-10-15 Filed 2026-10-19Bhatt Elizabeth Officer: President and COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (4,000) — exercise price 6.81
Disposed (D)4,0000—58,230Direct (D) Yes
F4
  • F4 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of October 28, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date.
Open filing 0001193125-26-425485 Read from the filing’s XML Dispute this row
2026-09-08 Filed 2026-09-10Patni Rajiv Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (275,000) — exercise price 37.37
Acquired (A)275,0000—275,000Direct (D) No
F1
  • F1 25% of the shares underlying this option will vest on August 24, 2027, and the remaining 75% of the shares underlying this option will vest in thirty-six substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
Open filing 0001193125-26-388033 Read from the filing’s XML Dispute this row
2026-09-01 Filed 2026-09-03Long Daniel D. Officer: SVP, Drug Discovery
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)3,3332.76
9,199.08

Derived: shares × price per share. Exact value 9199.08.

99,745Direct (D) Yes— Open filing 0001193125-26-382267 Read from the filing’s XML Dispute this row
2026-09-01 Filed 2026-09-03Long Daniel D. Officer: SVP, Drug Discovery
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)3,33337.8271
126,077.7243

Derived: shares × price per share. Exact value 126077.7243.

96,412Direct (D) Yes
F1, F2
  • F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 20, 2026.
  • F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.34 to $38.21. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Open filing 0001193125-26-382267 Read from the filing’s XML Dispute this row
2026-09-01 Filed 2026-09-03Long Daniel D. Officer: SVP, Drug Discovery
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (3,333) — exercise price 2.76
Disposed (D)3,3330—9,085Direct (D) Yes
F3
  • F3 1/48th of the shares subject to such option shall vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date.
Open filing 0001193125-26-382267 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14Third Rock Ventures V, L.P. 10% ownerThird Rock Ventures GP V, LP 10% ownerTRV GP V, LLC 10% ownerThird Rock Ventures VI, L.P. 10% ownerThird Rock Ventures GP VI, L.P. 10% ownerTRV GP VI, LLC 10% owner
S

Open market or private sale of non-derivative or derivative security

Common Stock
Acquired (A)147,05950.27
7,392,655.93

Derived: shares × price per share. Exact value 7392655.93.

6,068,532Direct (D) Yes
F1, F2, F3
  • F1 The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 26, 2026, previously adopted by the Reporting Person.
  • F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.05 to $50.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).
  • F3 These shares are directly held by Third Rock Ventures V, L.P. (TRV V). The general partner of TRV V is Third Rock Ventures GP V, L.P. (TRV GP V). The general partner of TRV GP V is TRV GP V, LLC (TRV GP V LLC). Each of TRV GP V and TRV GP V LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.
Open filing 0001193125-26-352692 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14Third Rock Ventures V, L.P. 10% ownerThird Rock Ventures GP V, LP 10% ownerTRV GP V, LLC 10% ownerThird Rock Ventures VI, L.P. 10% ownerThird Rock Ventures GP VI, L.P. 10% ownerTRV GP VI, LLC 10% owner
S

Open market or private sale of non-derivative or derivative security

Common Stock
Acquired (A)14151.08
7,202.28

Derived: shares × price per share. Exact value 7202.28.

6,068,391Direct (D) Yes
F1, F4, F3
  • F1 The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 26, 2026, previously adopted by the Reporting Person.
  • F4 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4).
  • F3 These shares are directly held by Third Rock Ventures V, L.P. (TRV V). The general partner of TRV V is Third Rock Ventures GP V, L.P. (TRV GP V). The general partner of TRV GP V is TRV GP V, LLC (TRV GP V LLC). Each of TRV GP V and TRV GP V LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.
Open filing 0001193125-26-352692 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerRA Capital Nexus Fund III, L.P. DirectorKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)746,50042.50
31,726,250

Derived: shares × price per share. Exact value 31726250.00.

4,777,415Indirect (I) See footnotesNo
F1, F2
  • F1 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund) and RA Capital Nexus Fund III, L.P. (the Nexus Fund III). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F2 Held directly by the Fund.
Open filing 0001231919-26-000938 Read from the filing’s XML Dispute this row
2026-08-12 Filed 2026-08-14RA CAPITAL MANAGEMENT, L.P. Director · 10% ownerRA Capital Healthcare Fund LP Director · 10% ownerRA Capital Nexus Fund III, L.P. DirectorKolchinsky Peter Director · 10% ownerShah Rajeev M. Director · 10% owner
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)746,50042.50
31,726,250

Derived: shares × price per share. Exact value 31726250.00.

725,443Indirect (I) See footnotesNo
F1, F3
  • F1 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund) and RA Capital Nexus Fund III, L.P. (the Nexus Fund III). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 Held directly by the Nexus Fund III.
Open filing 0001231919-26-000938 Read from the filing’s XML Dispute this row
2026-08-11 Filed 2026-08-13Bhatt Elizabeth Officer: President and COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)18,6816.81
127,217.61

Derived: shares × price per share. Exact value 127217.61.

192,890Direct (D) Yes— Open filing 0001193125-26-349810 Read from the filing’s XML Dispute this row
2026-08-11 Filed 2026-08-13Bhatt Elizabeth Officer: President and COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)6,3192.76
17,440.44

Derived: shares × price per share. Exact value 17440.44.

199,209Direct (D) Yes— Open filing 0001193125-26-349810 Read from the filing’s XML Dispute this row
2026-08-11 Filed 2026-08-13Bhatt Elizabeth Officer: President and COO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)25,00044
1,100,000

Derived: shares × price per share. Exact value 1100000.

174,209Direct (D) Yes
F1
  • F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on October 20, 2025.
Open filing 0001193125-26-349810 Read from the filing’s XML Dispute this row
2026-08-11 Filed 2026-08-13Bhatt Elizabeth Officer: President and COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (18,681) — exercise price 6.81
Disposed (D)18,6810—62,230Direct (D) Yes
F2
  • F2 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of October 28, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date.
Open filing 0001193125-26-349810 Read from the filing’s XML Dispute this row
2026-08-11 Filed 2026-08-13Bhatt Elizabeth Officer: President and COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (6,319) — exercise price 2.76
Disposed (D)6,3190—82,332Direct (D) Yes
F3
  • F3 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of August 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date.
Open filing 0001193125-26-349810 Read from the filing’s XML Dispute this row
2026-08-03 Filed 2026-08-05Long Daniel D. Officer: SVP, Drug Discovery
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)1,8162.76
5,012.16

Derived: shares × price per share. Exact value 5012.16.

98,228Direct (D) Yes— Open filing 0001193125-26-335820 Read from the filing’s XML Dispute this row
2026-08-03 Filed 2026-08-05Long Daniel D. Officer: SVP, Drug Discovery
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)1,5182.76
4,189.68

Derived: shares × price per share. Exact value 4189.68.

99,746Direct (D) Yes— Open filing 0001193125-26-335820 Read from the filing’s XML Dispute this row
2026-08-03 Filed 2026-08-05Long Daniel D. Officer: SVP, Drug Discovery
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,00033.9756
33,975.6

Derived: shares × price per share. Exact value 33975.6000.

98,746Direct (D) Yes
F1, F2
  • F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 20, 2026.
  • F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.39 to $34.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Open filing 0001193125-26-335820 Read from the filing’s XML Dispute this row
2026-08-03 Filed 2026-08-05Long Daniel D. Officer: SVP, Drug Discovery
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,33434.6805
80,944.287

Derived: shares × price per share. Exact value 80944.2870.

96,412Direct (D) Yes
F1, F3
  • F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 20, 2026.
  • F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.43 to $35.04. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Open filing 0001193125-26-335820 Read from the filing’s XML Dispute this row
2026-08-03 Filed 2026-08-05Long Daniel D. Officer: SVP, Drug Discovery
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (1,816) — exercise price 2.76
Disposed (D)1,8160—5,227Direct (D) Yes
F4
  • F4 1/48th of the shares subject to such option shall vest and become exercisable in substantially equal monthly installments on each monthly anniversary of August 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date.
Open filing 0001193125-26-335820 Read from the filing’s XML Dispute this row
2026-08-03 Filed 2026-08-05Long Daniel D. Officer: SVP, Drug Discovery
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (1,518) — exercise price 2.76
Disposed (D)1,5180—12,418Direct (D) Yes
F5
  • F5 1/48th of the shares subject to such option shall vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date.
Open filing 0001193125-26-335820 Read from the filing’s XML Dispute this row
2026-07-15 Filed 2026-07-17Bhatt Elizabeth Officer: President and COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)4,0006.81
27,240

Derived: shares × price per share. Exact value 27240.00.

178,209Direct (D) Yes— Open filing 0001193125-26-308073 Read from the filing’s XML Dispute this row
2026-07-15 Filed 2026-07-17Bhatt Elizabeth Officer: President and COO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)4,00033.9935
135,974

Derived: shares × price per share. Exact value 135974.0000.

174,209Direct (D) Yes
F1, F2
  • F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on October 20, 2025.
  • F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.49 to $34.24. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Open filing 0001193125-26-308073 Read from the filing’s XML Dispute this row
2026-07-15 Filed 2026-07-17Bhatt Elizabeth Officer: President and COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (4,000) — exercise price 6.81
Disposed (D)4,0000—80,911Direct (D) Yes
F3
  • F3 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of October 28, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date.
Open filing 0001193125-26-308073 Read from the filing’s XML Dispute this row
2026-07-01 Filed 2026-07-02Long Daniel D. Officer: SVP, Drug Discovery
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)3,3332.76
9,199.08

Derived: shares × price per share. Exact value 9199.08.

99,745Direct (D) Yes— Open filing 0001193125-26-295106 Read from the filing’s XML Dispute this row
2026-07-01 Filed 2026-07-02Long Daniel D. Officer: SVP, Drug Discovery
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,10034.0964
71,602.44

Derived: shares × price per share. Exact value 71602.4400.

97,645Direct (D) Yes
F1, F2
  • F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 20, 2026.
  • F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.49 to $34.46. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Open filing 0001193125-26-295106 Read from the filing’s XML Dispute this row
2026-07-01 Filed 2026-07-02Long Daniel D. Officer: SVP, Drug Discovery
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,23334.8141
42,925.7853

Derived: shares × price per share. Exact value 42925.7853.

96,412Direct (D) Yes
F1, F3
  • F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 20, 2026.
  • F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.52 to $35.10. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Open filing 0001193125-26-295106 Read from the filing’s XML Dispute this row
2026-07-01 Filed 2026-07-02Long Daniel D. Officer: SVP, Drug Discovery
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (3,333) — exercise price 2.76
Disposed (D)3,3330—7,043Direct (D) Yes
F4
  • F4 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of August 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date.
Open filing 0001193125-26-295106 Read from the filing’s XML Dispute this row
2026-06-29 Filed 2026-06-30Shaikhly Samira Officer: Chief People Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)2,1786.81
14,832.18

Derived: shares × price per share. Exact value 14832.18.

2,971Direct (D) Yes— Open filing 0001193125-26-291059 Read from the filing’s XML Dispute this row
2026-06-29 Filed 2026-06-30Shaikhly Samira Officer: Chief People Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,17835.18
76,622.04

Derived: shares × price per share. Exact value 76622.04.

793Direct (D) Yes
F1
  • F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on October 31, 2025.
Open filing 0001193125-26-291059 Read from the filing’s XML Dispute this row
2026-06-29 Filed 2026-06-30Shaikhly Samira Officer: Chief People Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (2,178) — exercise price 6.81
Disposed (D)2,1780—20,865Direct (D) Yes
F2
  • F2 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of October 28, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date.
Open filing 0001193125-26-291059 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,925 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,176 filings read.

Showing 1–50 of 179

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
TRV GP V, LLC 6,068,391 SH237,456,140 dollarsLower by 147,200 Prior quarter: 6,215,591Open filing 0001193125-26-463550 Filed 2026-11-16 Dispute this row
RA CAPITAL MANAGEMENT, L.P. 5,502,858 SH215,326,834 dollarsLower by 1,493,000 Prior quarter: 6,995,858Open filing 0001104659-26-128411 Filed 2026-11-16 Dispute this row
Driehaus Capital Management LLC 4,273,431 SH167,219,355 dollarsLower by 159,627 Prior quarter: 4,433,058Open filing 0000938206-26-000066 Filed 2026-11-16 Dispute this row
TRV GP VI, LLC 4,211,659 SH164,802,217 dollarsUnchanged Prior quarter: 4,211,659Open filing 0001193125-26-463547 Filed 2026-11-16 Dispute this row
SAMSARA BIOCAPITAL, LLC 3,066,453 SH119,990,306 dollarsLower by 82,675 Prior quarter: 3,149,128Open filing 0001744967-26-000014 Filed 2026-11-16 Dispute this row
GOLDMAN SACHS GROUP INC Partly reported under another manager3,018,431 SH118,111,215 dollarsLower by 44,335 Prior quarter: 3,062,766Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row
BlackRock, Inc. Partly reported under another manager2,074,603 SH81,179,215 dollarsHigher by 142,515 Prior quarter: 1,932,088Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
Siren, L.L.C. Partly reported under another manager1,700,000 SH66,521,000 dollarsLower by 200,000 Prior quarter: 1,900,000Open filing 0002005245-26-000013 Filed 2026-11-12 Dispute this row
Janus Henderson Group Ltd. Partly reported under another manager1,611,125 SH63,091,655 dollarsNot in the prior quarter’s filings read Open filing 0001085146-26-000952 Filed 2026-11-16 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 1,354,288 SH52,993,289 dollarsHigher by 132,615 Prior quarter: 1,221,673Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
PRIMECAP MANAGEMENT CO/CA/ 1,354,261 SH52,992,233 dollarsHigher by 186,879 Prior quarter: 1,167,382Open filing 0000763212-26-000037 Filed 2026-11-12 Dispute this row
Avoro Capital Advisors LLC 1,300,000 SH50,869,000 dollarsLower by 37,500 Prior quarter: 1,337,500Open filing 0001104659-26-127608 Filed 2026-11-16 Dispute this row
First Light Asset Management, LLC 1,164,271 SH45,557,924 dollarsHigher by 201,011 Prior quarter: 963,260Open filing 0001999371-26-025524 Filed 2026-11-16 Dispute this row
ADAR1 Capital Management, LLC 974,396 SH38,128,115 dollarsHigher by 33,649 Prior quarter: 940,747Open filing 0001940272-26-000033 Filed 2026-11-16 Dispute this row
FMR LLC Partly reported under another manager865,636 SH33,872,337 dollarsHigher by 842,396 Prior quarter: 23,240Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
STATE STREET CORP Partly reported under another manager798,146 SH31,231,453 dollarsHigher by 145,516 Prior quarter: 652,630Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager686,792 SH26,879,965 dollarsHigher by 7,629 Prior quarter: 679,163Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
LOOMIS SAYLES CO L P Partly reported under another manager646,663 SH25,303,923 dollarsHigher by 21,911 Prior quarter: 624,752Open filing 0000312348-26-000039 Filed 2026-11-12 Dispute this row
PERCEPTIVE ADVISORS LLC 567,479 SH22,205,453 dollarsNot in the prior quarter’s filings read Open filing 0001012975-26-001063 Filed 2026-11-16 Dispute this row
Casdin Capital, LLC 553,268 SH21,649,377 dollarsUnchanged Prior quarter: 553,268Open filing 0000919574-26-008113 Filed 2026-11-16 Dispute this row
Catalio Capital Management, LP 454,015 SH17,765,607 dollarsLower by 82,137 Prior quarter: 536,152Open filing 0001958125-26-000012 Filed 2026-11-16 Dispute this row
ALGERT GLOBAL LLC Partly reported under another manager451,116 SH17,652,169 dollarsHigher by 53,629 Prior quarter: 397,487Open filing 0001275218-26-000018 Filed 2026-11-17 Dispute this row
Soleus Capital Management, L.P. 330,000 SH12,912,900 dollarsHigher by 55,000 Prior quarter: 275,000Open filing 0001802630-26-000008 Filed 2026-11-16 Dispute this row
BRAIDWELL LP 328,240 SH12,844,031 dollarsNot in the prior quarter’s filings read Open filing 0001420506-26-002894 Filed 2026-11-16 Dispute this row
Balyasny Asset Management L.P. 323,271 SH12,649,594 dollarsLower by 27,171 Prior quarter: 350,442Open filing 0001193125-26-463223 Filed 2026-11-16 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 253,253 SH9,909,790 dollarsHigher by 23,069 Prior quarter: 230,184Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
D. E. Shaw Co., Inc. Partly reported under another manager233,199 SH9,125,077 dollarsHigher by 186,716 Prior quarter: 46,483Open filing 0001104659-26-128287 Filed 2026-11-16 Dispute this row
Universal- Beteiligungs- und Servicegesellschaft mbH Partly reported under another manager223,576 SH8,748,529 dollarsHigher by 874 Prior quarter: 222,702Open filing 0002057170-26-000022 Filed 2026-11-10 Dispute this row
Nuveen, LLC Partly reported under another manager209,685 SH8,204,974 dollarsHigher by 161,456 Prior quarter: 48,229Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 208,899 SH8,174,218 dollarsHigher by 21,858 Prior quarter: 187,041Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row
MORGAN STANLEY Partly reported under another manager207,006 SH8,100,146 dollarsHigher by 72,629 Prior quarter: 134,377Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager202,170 SH7,910,912 dollarsHigher by 1,039 Prior quarter: 201,131Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
ADAGE CAPITAL PARTNERS GP, L.L.C. 199,000 SH7,786,870 dollarsNot in the prior quarter’s filings read Open filing 0001172661-26-005200 Filed 2026-11-16 Dispute this row
Kalehua Capital Management LLC 194,544 SH7,612,507 dollarsLower by 194,544 Prior quarter: 389,088Open filing 0002106181-26-000010 Filed 2026-11-13 Dispute this row
VANGUARD FIDUCIARY TRUST CO 171,681 SH6,717,878 dollarsHigher by 6,025 Prior quarter: 165,656Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
Qube Research Technologies Ltd 162,879 SH6,373,455 dollarsNot in the prior quarter’s filings read Open filing 0001729829-26-000018 Filed 2026-11-13 Dispute this row
UBS Group AG Partly reported under another manager157,186 SH6,150,688 dollarsHigher by 67,312 Prior quarter: 89,874Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
AMERIPRISE FINANCIAL INC Partly reported under another manager152,156 SH5,953,863 dollarsNot in the prior quarter’s filings read Open filing 0001193125-26-463125 Filed 2026-11-16 Dispute this row
Longaeva Partners L.P. Partly reported under another manager142,259 SH5,566,595 dollarsLower by 155,912 Prior quarter: 298,171Open filing 0001193125-26-463222 Filed 2026-11-16 Dispute this row
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP Partly reported under another manager131,731 SH5,154,634 dollarsHigher by 57,082 Prior quarter: 74,649Open filing 0001164508-26-000060 Filed 2026-11-13 Dispute this row
Ikarian Capital, LLC Option: Call 127,200 SH4,977,336 dollarsNot in the prior quarter’s filings read Open filing 0001420506-26-002881 Filed 2026-11-16 Dispute this row
TWO SIGMA INVESTMENTS, LP 112,749 SH4,411,868 dollarsLower by 108,136 Prior quarter: 220,885Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row
DIMENSIONAL FUND ADVISORS LP Partly reported under another manager107,373 SH4,201,505 dollarsHigher by 32,064 Prior quarter: 75,309Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row
NEUBERGER BERMAN GROUP LLC 104,762 SH4,099,337 dollarsNot in the prior quarter’s filings read Open filing 0001465109-26-000128 Filed 2026-11-13 Dispute this row
Ikarian Capital, LLC 100,047 SH3,914,839 dollarsNot in the prior quarter’s filings read Open filing 0001420506-26-002881 Filed 2026-11-16 Dispute this row
Ikarian Capital, LLC Option: Put 95,200 SH3,725,176 dollarsNot in the prior quarter’s filings read Open filing 0001420506-26-002881 Filed 2026-11-16 Dispute this row
XTX Topco Ltd Partly reported under another manager93,034 SH3,640,420 dollarsHigher by 38,545 Prior quarter: 54,489Open filing 0001828301-26-000009 Filed 2026-11-16 Dispute this row
FEDERATED HERMES, INC. Partly reported under another manager92,413 SH3,616,121 dollarsHigher by 5,660 Prior quarter: 86,753Open filing 0001623632-26-001675 Filed 2026-11-12 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager85,489 SH3,345,185 dollarsHigher by 188 Prior quarter: 85,301Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
AMERICAN CENTURY COMPANIES INC Partly reported under another manager79,358 SH3,105,279 dollarsHigher by 18,385 Prior quarter: 60,973Open filing 0000748054-26-000008 Filed 2026-11-12 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • Jupiter Topco LLC 1,307,500 SH
  • Caption Management, LLC 440,000 SH
  • Caption Management, LLC 200,000 SH
  • TUDOR INVESTMENT CORP ET AL 200,000 SH
  • Sixth Street Partners Management Company, L.P. 187,041 SH
  • Woodline Partners LP 185,535 SH
  • TUDOR INVESTMENT CORP ET AL 100,000 SH
  • CITADEL ADVISORS LLC 81,800 SH
  • DIADEMA PARTNERS LP 59,700 SH
  • JANE STREET GROUP, LLC 57,200 SH
  • JANE STREET GROUP, LLC 45,552 SH
  • RENAISSANCE TECHNOLOGIES LLC 41,419 SH
  • Caption Management, LLC 38,006 SH
  • SUSQUEHANNA INTERNATIONAL GROUP, LLP 33,900 SH
  • TUDOR INVESTMENT CORP ET AL 28,966 SH
  • Trexquant Investment LP 25,645 SH
  • FOX RUN MANAGEMENT, L.L.C. 22,038 SH
  • FRED ALGER MANAGEMENT, LLC 20,958 SH
  • CIBC Bancorp USA Inc. 7,222 SH
  • Rangeley Capital, LLC 7,200 SH
  • SIMPLEX TRADING, LLC 2,500 SH
  • BERTHEL, FISHER COMPANY FINANCIAL SERVICES, INC. 1,295 SH
  • MERCER GLOBAL ADVISORS INC /ADV 630 SH
  • Persistent Asset Partners Ltd 152 SH
  • Caitong International Asset Management Co., Ltd 77 SH
  • Integrated Wealth Concepts LLC 51 SH
  • Ameritas Advisory Services, LLC 18 SH
  • NATIONAL BANK OF CANADA /FI/ 7 SH
  • Global Retirement Partners, LLC 3 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Third Rock Ventures V, L.P. Common Stock, $0.001 par value per share13.06,068,39109/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001193125-26-463540 Dispute this row
Third Rock Ventures GP V, L.P. Common Stock, $0.001 par value per share13.06,068,39109/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001193125-26-463540 Dispute this row
TRV GP V, LLC Common Stock, $0.001 par value per share13.06,068,39109/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001193125-26-463540 Dispute this row
Third Rock Ventures VI, L.P. Common Stock, $0.001 par value per share9.04,211,65909/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001193125-26-463540 Dispute this row
Third Rock Ventures GP VI, L.P. Common Stock, $0.001 par value per share9.04,211,65909/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001193125-26-463540 Dispute this row
TRV GP VI, LLC Common Stock, $0.001 par value per share9.04,211,65909/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001193125-26-463540 Dispute this row
RA Capital Management, L.P. Common Stock, par value $0.001 per share11.85,525,324.0008/12/2026 Filed 2026-08-14SCHEDULE 13D/AAmendment 1Open filing 0001346824-26-000228 Dispute this row
Peter Kolchinsky Common Stock, par value $0.001 per share11.85,525,324.0008/12/2026 Filed 2026-08-14SCHEDULE 13D/AAmendment 1Open filing 0001346824-26-000228 Dispute this row
Rajeev Shah Common Stock, par value $0.001 per share11.85,525,324.0008/12/2026 Filed 2026-08-14SCHEDULE 13D/AAmendment 1Open filing 0001346824-26-000228 Dispute this row
RA Capital Healthcare Fund, L.P. Common Stock, par value $0.001 per share10.24,777,415.0008/12/2026 Filed 2026-08-14SCHEDULE 13D/AAmendment 1Open filing 0001346824-26-000228 Dispute this row
DRIEHAUS CAPITAL MANAGEMENT LLC Common Stock9.834,433,05806/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 3Open filing 0000938206-26-000037 Dispute this row
BIOTECHNOLOGY VALUE FUND L P Common Stock, $0.001 par value per share2.0919,814.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0000921895-26-000473 Dispute this row
BVF I GP LLC Common Stock, $0.001 par value per share2.0919,814.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0000921895-26-000473 Dispute this row
BIOTECHNOLOGY VALUE FUND II LP Common Stock, $0.001 par value per share1.5671,492.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0000921895-26-000473 Dispute this row
BVF II GP LLC Common Stock, $0.001 par value per share1.5671,492.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0000921895-26-000473 Dispute this row
Biotechnology Value Trading Fund OS LP Common Stock, $0.001 par value per share0.2104,119.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0000921895-26-000473 Dispute this row
BVF Partners OS Ltd. Common Stock, $0.001 par value per share0.2104,119.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0000921895-26-000473 Dispute this row
BVF GP HOLDINGS LLC Common Stock, $0.001 par value per share3.61,591,306.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0000921895-26-000473 Dispute this row
BVF PARTNERS L P/IL Common Stock, $0.001 par value per share3.81,720,782.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0000921895-26-000473 Dispute this row
BVF INC/IL Common Stock, $0.001 par value per share3.81,720,782.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0000921895-26-000473 Dispute this row
LAMPERT MARK N Common Stock, $0.001 par value per share3.81,720,782.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0000921895-26-000473 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,686,506 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015103,592
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,124

Filings made before the SEC required XML are listed, not extracted.

Back to Septerna, Inc.